Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open label Phase II clinical trial to evaluate the efficacy and safety
of apatinib combined with irinotecan and S-1 (ApaIRIS) in treating Patients with metastatic
pancreatic cancer after chemotherapy with albumin-bound paclitaxel plus gemcitabine regimen